# Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome

> **NCT00135356** · PHASE4 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 219 (actual)

## Conditions studied

- HIV-Associated Lipodystrophy Syndrome

## Interventions

- **DRUG:** Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)
- **DRUG:** continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)

## Key facts

- **NCT ID:** NCT00135356
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2007-07
- **Final completion:** 2008-06
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2010-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00135356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00135356, "Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00135356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*